Skip to main content

Advertisement

SpringerLink
Log in

Alteration in the Balance of Prosurvival and Proapoptotic Signalling Pathways Leads to Sequence-Dependent Synergism Between Docetaxel and Sorafenib in Human Non-small Cell Lung Cancer Cell Lines

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

To examine the antiproliferative effect of the combination of docetaxel and sorafenib, applied to the representative non-small cell lung cancer cell line A549 cells either wild type or with acquired resistance to docetaxel (A549/D). The aim of this study is to evaluate the synergistic effect of combination treatment on cell growth inhibition and to elucidate the involved molecular mechanisms. A549 cells with acquired resistance to docetaxel were established by continuous exposure to docetaxel. We examined the effect of different combinatorial treatment on cell proliferation and cell cycle distribution. In addition, the effect of combinatorial treatments on proliferative and apoptotic signalling pathway were studied. Our results showed that the synergistic effect presented when A549 cells were treated with docetaxel followed by sorafenib or when A549/D cells were treated in reverse sequence. Furthermore, we suggested that synergistic effect in A549/D cells was caused by inhibiting P-gp function and altering in the balance of growth and apoptotic signalling pathways. Our data suggested a potential role of sorafenib in chemosensitizing docetaxel-resistant cancer cells. This study also provides molecular evidence for applying different therapeutic strategies for patients with different genetic and proteomic profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics, 2009. CA Cancer Journal for Clinicians, 59(4), 225–249.

    Article  Google Scholar 

  2. Society AC. (2009). Cancer facts and figures. Atlanta: American Cancer Society, Inc.

    Google Scholar 

  3. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine, 346(2), 92–98.

    Article  CAS  PubMed  Google Scholar 

  4. Wilhelm, S., & Chien, D. S. (2002). BAY 43-9006: preclinical data. Current Pharmaceutical Design, 8(25), 2255–2257.

    Article  CAS  PubMed  Google Scholar 

  5. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64(19), 7099–7109.

    Article  CAS  PubMed  Google Scholar 

  6. Rahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005). Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. The Journal of Biological Chemistry, 280(42), 35217–35227.

    Article  CAS  PubMed  Google Scholar 

  7. Takezawa, K., Okamoto, I., Yonesaka, K., Hatashita, E., Yamada, Y., Fukuoka, M., et al. (2009). Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Research, 69(16), 6515–6521.

    Article  CAS  PubMed  Google Scholar 

  8. Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research, 66(24), 11851–11858.

    Article  CAS  PubMed  Google Scholar 

  9. Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., et al. (2005). The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene, 24(46), 6861–6869.

    Article  CAS  PubMed  Google Scholar 

  10. Carter, C. A., Chen, C., Brink, C., Vincent, P., Maxuitenko, Y. Y., Gilbert, K. S., et al. (2007). Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology, 59(2), 183–195.

    Article  CAS  PubMed  Google Scholar 

  11. Ulivi, P., Arienti, C., Zoli, W., Scarsella, M., Carloni, S., Fabbri, F., et al. (2010). In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. Current Cancer Drug Targets, 10(6), 600–610.

    Article  CAS  PubMed  Google Scholar 

  12. Bareford, M. D., Hamed, H. A., Tang, Y., Cruickshanks, N., Burow, M. E., Fisher, P. B., et al. (2011). Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy, 7(10), 1261–1262.

    Article  CAS  PubMed  Google Scholar 

  13. Pasqualetti, G., Ricciardi, S., Mey, V., Del Tacca, M., & Danesi, R. (2011). Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung Cancer, 74(2), 197–205.

    Article  PubMed  Google Scholar 

  14. Flaherty, K. T., Schiller, J., Schuchter, L. M., Liu, G., Tuveson, D. A., Redlinger, M., et al. (2008). A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clinical Cancer Research, 14(15), 4836–4842.

    Article  CAS  PubMed  Google Scholar 

  15. Scagliotti, G., Novello, S., von Pawel, J., Reck, M., Pereira, J. R., Thomas, M., et al. (2010). Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 28(11), 1835–1842.

    Article  CAS  PubMed  Google Scholar 

  16. Okamoto, I., Miyazaki, M., Morinaga, R., Kaneda, H., Ueda, S., Hasegawa, Y., et al. (2010). Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Investigational New Drugs, 28(6), 844–853.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Montero, A., Fossella, F., Hortobagyi, G., & Valero, V. (2005). Docetaxel for treatment of solid tumours: a systematic review of clinical data. The Lancet Oncology, 6(4), 229–239.

    Article  CAS  PubMed  Google Scholar 

  18. Pan, F., Tian, J., Zhang, X., Zhang, Y., & Pan, Y. (2011). Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology, 137(9), 1397–1408.

    Article  CAS  PubMed  Google Scholar 

  19. Herbst, R. S., Sun, Y., Eberhardt, W. E., Germonpre, P., Saijo, N., Zhou, C., et al. (2010). Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. The Lancet Oncology, 11(7), 619–626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Heymach, J. V., Johnson, B. E., Prager, D., Csada, E., Roubec, J., Pesek, M., et al. (2007). Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. Journal of clinical oncology, 25(27), 4270–4277.

    Article  CAS  PubMed  Google Scholar 

  21. Lo Nigro, C., Maffi, M., Fischel, J. L., Formento, P., Milano, G., & Merlano, M. (2008). The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU International, 102(5), 622–627.

    Article  PubMed  Google Scholar 

  22. Chou, T. C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27–55.

    Article  CAS  PubMed  Google Scholar 

  23. Cheng, H., An, S. J., Zhang, X. C., Dong, S., Zhang, Y. F., Chen, Z. H., et al. (2011). In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 67(3), 637–646.

    Article  CAS  PubMed  Google Scholar 

  24. Jordan, M. A., & Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nature Reviews Cancer, 4(4), 253–265.

    Article  CAS  PubMed  Google Scholar 

  25. Morelli, M. P., Cascone, T., Troiani, T., De Vita, F., Orditura, M., Laus, G., et al. (2005). Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of Oncology, 16(4), iv61–iv68.

    PubMed  Google Scholar 

  26. Conrad, C., Ischenko, I., Kohl, G., Wiegand, U., Guba, M., Yezhelyev, M., et al. (2007). Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anti-Cancer Drugs, 18(5), 569–579.

    Article  CAS  PubMed  Google Scholar 

  27. Mahaffey, C. M., Davies, A. M., Lara, P. N, Jr, Pryde, B., Holland, W., Mack, P. C., et al. (2007). Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clinical Lung Cancer, 8(9), 548–553.

    Article  CAS  PubMed  Google Scholar 

  28. Sarkar, S., Mazumdar, A., Dash, R., Sarkar, D., Fisher, P. B., & Mandal, M. (2011). ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. Journal of Cellular Physiology, 226(2), 375–384.

    Article  CAS  PubMed  Google Scholar 

  29. McHugh, L. A., Kriajevska, M., Mellon, J. K., & Griffiths, T. R. (2007). Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens–evidence of schedule-dependent synergy. Urology, 69(2), 390–394.

    Article  PubMed  Google Scholar 

  30. Monteverde, M., Tonissi, F., Fischel, J. L., Etienne-Grimaldi, M. C., Milano, G., Merlano, M., et al. (2011). Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line. Urologic Oncology, 31(6), 776–786.

    Article  PubMed  Google Scholar 

  31. Collins, D. M., Crown, J., O’Donovan, N., Devery, A., O’Sullivan, F., O’Driscoll, L., et al. (2010). Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Investigational New Drugs, 28(4), 433–444.

    Article  CAS  PubMed  Google Scholar 

  32. Flaig, T. W., Su, L. J., McCoach, C., Li, Y., Raben, D., Varella-Garcia, M., et al. (2009). Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU International, 103(12), 1729–1737.

    Article  CAS  PubMed  Google Scholar 

  33. Perez-Soler, R., Piperdi, B., Haigentz, M., Ling, Y-H. (2004). Determinants of sensitivity to the EGFR TK inhibitor erlotinib (E) in a panel of NSCLC cell lines. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 22 (14), 7026.

  34. Li, T., Ling, Y. H., Goldman, I. D., & Perez-Soler, R. (2007). Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clinical Cancer Research, 13(11), 3413–3422.

    Article  CAS  PubMed  Google Scholar 

  35. Wang, T., Wei, J., Qian, X., Ding, Y., Yu, L., & Liu, B. (2008). Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Letters, 262(2), 214–222.

    Article  CAS  PubMed  Google Scholar 

  36. Yamanaka, K., Nakata, M., Kaneko, N., Fushiki, H., Kita, A., Nakahara, T., et al. (2011). YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. International Journal of Oncology, 39(3), 569–575.

    CAS  PubMed  Google Scholar 

  37. Nakahara, T., Yamanaka, K., Hatakeyama, S., Kita, A., Takeuchi, M., Kinoyama, I., et al. (2011). YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anti-Cancer Drugs, 22(5), 454–462.

    Article  CAS  PubMed  Google Scholar 

  38. Yoon, D. H., Shin, J. S., Jin, D. H., Hong, S. W., Jung, K. A., Kim, S. M., et al. (2012). The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Anticancer Research, 32(5), 1681–1688.

    CAS  PubMed  Google Scholar 

  39. Ling, X., Bernacki, R. J., Brattain, M. G., & Li, F. (2004). Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. The Journal of Biological Chemistry, 279(15), 15196–15203.

    Article  CAS  PubMed  Google Scholar 

  40. Uchida, H., Tanaka, T., Sasaki, K., Kato, K., Dehari, H., Ito, Y., et al. (2004). Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Molecular Therapy, 10(1), 162–171.

    Article  CAS  PubMed  Google Scholar 

  41. Kirkin, V., Joos, S., & Zornig, M. (2004). The role of Bcl-2 family members in tumorigenesis. Biochimica Biophysica Acta, 1644(2–3), 229–249.

    Article  CAS  Google Scholar 

  42. Ciardiello, F., Caputo, R., Borriello, G., Del Bufalo, D., Biroccio, A., Zupi, G., et al. (2002). ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. International Journal of Cancer, 98(3), 463–469.

    Article  CAS  Google Scholar 

  43. Maraz, A., Furak, J., Palfoldi, R., Eller, J., Szanto, E., Kahan, Z., et al. (2011). Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Research, 31(4), 1431–1436.

    PubMed  Google Scholar 

  44. Tan, N., Malek, M., Zha, J., Yue, P., Kassees, R., Berry, L., et al. (2011). Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clinical Cancer Research, 17(6), 1394–1404.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Taizhou Second People’s Hospital, Jiangyan, 225599, China

    Xuejun He

  2. Department of Oncology, The Affiliated Jiangyin People’s Hospital, School of Medicine, Southeast University, Jiangyin, 214400, China

    Tingrong Zhang

Authors
  1. Xuejun He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tingrong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tingrong Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, X., Zhang, T. Alteration in the Balance of Prosurvival and Proapoptotic Signalling Pathways Leads to Sequence-Dependent Synergism Between Docetaxel and Sorafenib in Human Non-small Cell Lung Cancer Cell Lines. Cell Biochem Biophys 68, 411–418 (2014). https://doi.org/10.1007/s12013-013-9722-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-013-9722-5

Keywords

Search

Navigation